(1)

Claims:

1. Use of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl]-benzamide of the formula I

or a pharmaceutically acceptable salt thereof for the manufacture of pharmaceutical compositions for the treatment of a pulmonary fibrosis disease.

- 2. The use according to claim 1, wherein the pulmonary fibrosis disease is an interstitial lung disease.
- 3. The use according to claim 1, wherein the pulmonary fibrosis disease is an idiopathic pulmonary fibrosis.
- 4. Use of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl]-benzamide of the formula I or a pharmaceutically acceptable salt thereof in the treatment of pulmonary fibrosis.
- 5. A method of treating a human subject suffering from pulmonary fibrosis which comprises administering to a said human in need of such treatment a dose, effective against pulmonary fibrosis, of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl]-benzamide of the formula I or a pharmaceutically acceptable salt thereof.
- 6. Use according to any one of claims 1 to 4 or method according to claim 5 wherein the pulmonary fibrosis is induced by asbestos.
- 7. A method of administering to a human subject suffering from pulmonary fibrosis which comprises administering a pharmaceutically effective amount of 4-(4-methylpiperazin-1-

WO 2004/002489 PCT/IB2003/002794

- 13 -

.,.

ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I or a pharmaceutically acceptable salt thereof to said human subject once daily for a period exceeding 3 months.

- 8. Use or method according to any one of claims 1 to 7 wherein 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I is in the form of a pharmaceutically acceptable acid addition salt thereof.
- 9. Use or method according to claim 8 wherein 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I is in the monomethane sulfonate salt form thereof.
- 10. Use or method according to claim 9 wherein 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I is in the beta crystal form of the mesylate salt.
- 11. Use or method according to claim 11 wherein a daily dose of a monomethanesulfonate salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl]-benzamide of the formula I in the beta crystal form corresponding to 200 to 800 mg of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl]-benzamide of the formula I free base is administered to an adult human.